Humacyte, Inc. (HUMA) insider buying and selling

NASDAQ: HUMA · Source: SEC Form 4 filings · Latest trade reported

In the last 90 days at Humacyte, Inc. (HUMA), 1 insider made 2 open-market purchases worth $25K and there were no open-market sales, as reported on SEC Form 4. Over the last 12 months, 3 insiders bought $85K of the stock, led by Kathleen Sebelius (Director), who bought $50K on May 19, 2026; 2 insiders sold $82K, of which $82K was scheduled or tax-related.

Insider buys, 90 days
2
$25K · 1 insider
Insider sales, 90 days
0
$0 · 0 insiders
Insider buys, 12 months
4
$85K · 3 insiders
Insider sales, 12 months
2
$82K · 2 insiders

This is the public summary. Create a free account to see HUMA’s AI Signal, the price chart with every insider trade plotted, and each insider’s track record.

Unlock HUMA

Recent open-market insider trades

Trades by the same insider within a week are shown as one line.

Open-market insider trades at Humacyte, Inc.
DateInsiderTypeSharesPriceValue
Keith Anthony Jones
Director
Open market purchase
2 trades
40,000avg. $0.62$25K
Kathleen Sebelius
Director
Open market purchase56,818$0.88$50K
Michael T. Constantino
Director
Open market purchase11,000$0.89$10K

Scheduled and tax-related sales

Sales made under a pre-arranged 10b5-1 plan or to cover tax on vesting shares. They are listed separately because they are not a fresh decision to sell.

Scheduled and tax-related insider sales at Humacyte, Inc.
DateInsiderTypeSharesPriceValue
Dale A. Sander
CFO
10b5-1 sale45,887$0.90$41K
Shamik J Parikh
Chief Medical Officer
10b5-1 sale45,887$0.90$41K

What the HUMA insider trades really mean

The table above is the public summary. With an Insider Intel account you get the analysis behind it, for Humacyte, Inc. and every other stock we track:

The AI Signal weighs:Insider buyingAnalyst ratingPrice upsideAI OutlookInsider track recordBreakout pressure

Plus AI summaries, the latest news for each stock, and an AI assistant you can ask questions about any of it.

Get started free with HUMA Insider Intel tracks insider activity at 3,154 companies right now. The Free plan includes full price charts and trade history, watchlists and email alerts.

Questions about HUMA insider trading

Who bought Humacyte, Inc. (HUMA) stock recently?

Insiders who bought Humacyte, Inc. stock on the open market in the last 12 months: Kathleen Sebelius ($50K), Keith Anthony Jones ($25K), Michael T. Constantino ($10K). The most recent purchase was reported on Aug 20, 2026.

Are insiders buying or selling HUMA?

Over the last 12 months insiders were net buyers of HUMA on discretionary trades: $85K bought against $0 sold (scheduled and tax-related sales excluded).

What is a sell-to-cover or 10b5-1 sale?

A 10b5-1 sale is scheduled in advance under a pre-arranged plan, and a sell-to-cover sale is made to pay tax on vesting shares. Neither is a fresh decision to sell, so they say less about an insider's view than a discretionary sale.

Where does this data come from?

Officers, directors and large shareholders report their trades to the SEC on Form 4. This page lists the open-market purchases and sales by individual insiders from those public filings; funds and other institutions are not shown.

Other stocks with recent insider buying

Ready to see HUMA in full?

Create a free account and open its chart, score and alerts.

Create your free account

How to read this page

Officers, directors and large shareholders must report their trades in company shares to the SEC on Form 4. This page lists open-market purchases and sales by individual insiders: trades made on the stock exchange at the going price. Funds and other institutions are not shown here.

Information from SEC EDGAR Form 4 filings, shown for general information only. It is not financial advice and does not recommend buying or selling any security. Trades are shown by transaction date and may be reported up to two business days later.